Press releases | WebDisclosure

Basculer en Français

9571	Companies
189535	Keywords
121135	Articles
101076	Press releases

Home
Press releases

PRESS RELEASE

published on 03/22/2024 at 07:30, 1 year 9 months ago

Bike24 Holding AG: Strong double-digit growth rates in localized markets and full-bike segment but ongoing weak consumer sentiment in core markets during FY 2023
BIKE24 Holding AG reported strong double-digit growth rates in localized markets and the full-bike segment despite weak consumer sentiment in core markets during FY 2023. The company expects sales growth of 1-5% and an adj. EBITDA margin of 0.7-4.2% for 2024

FY 2023 Results Bike24 Holding AG Localized Markets Full-bike Segment Sales Growth Forecast
PRESS RELEASE

published on 03/22/2024 at 07:03, 1 year 9 months ago

EQS-Adhoc: Dexus Finance Pty Limited: Correction: Appendix 3G - Notification regarding unquoted securities and Appendix 3H – notification of cessation of securities
Dexus Finance Pty Limited corrects inaccuracies in Appendix 3G and 3H notifications regarding Performance Rights vesting and cessation

Dexus Finance Pty Limited ASX Announcement Performance Rights Appendix 3G Appendix 3H
PRESS RELEASE

published on 03/22/2024 at 07:01, 1 year 9 months ago

Evolva Holding in liquidation SA publishes liquidation interim financial statements and agenda for 2024 annual general meeting; reports positive purchase price adjustment of CHF 1,929,000 under SPA; g
Evolva Holding SA in liquidation publishes liquidation interim financial statements and agenda for 2024 annual general meeting; reports a positive purchase price adjustment of CHF 1,929,000 under SPA

Liquidation Evolva Holding SA AGM 2024 Purchase Price Adjustment Interim Financial Statements
PRESS RELEASE

published on 03/22/2024 at 07:01, 1 year 9 months ago

Biophytis a présenté son protocole de phase 3 dans le traitement de la sarcopénie
Biophytis a présenté son protocole de phase 3 dans le traitement de la sarcopénie lors de l’ICFSR. L'étude SARA-31 vise à évaluer l'efficacité de RuvembriTM. La société recherche des partenaires pharmaceutiques pour le développer

Biophytis RuvembriTM Sarcopénie ICFSR Protocole De Phase 3
PRESS RELEASE

published on 03/22/2024 at 07:01, 1 year 9 months ago

Biophytis presented its phase 3 protocol in the treatment of sarcopenia
Biophytis presented its phase 3 protocol for treating sarcopenia with Ruvembri at ICFSR conference, showing promising results in phase 2 study

Biophytis Ruvembri Phase 3 Protocol Sarcopenia Treatment ICFSR Conference
PRESS RELEASE

published on 03/22/2024 at 07:00, 1 year 9 months ago

Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
Relief Therapeutics enters into exclusive U.S. license and supply agreement with Eton Pharmaceuticals for PKU GOLIKE. Partnership aims to increase awareness and adoption of PKU medical formula

Metabolic Diseases Relief Therapeutics Eton Pharmaceuticals PKU GOLIKE Exclusive License
PRESS RELEASE

published on 03/22/2024 at 07:00, 1 year 9 months ago

CEWE is planning further turnover and earnings growth in 2024
CEWE plans further turnover and earnings growth in 2024 with turnover expected to reach up to EUR 820 million and EBIT up to EUR 87 million. Results for 2023 show strong performance in all business segments

Earnings Growth Photofinishing 2024 Forecast Turnover Growth CEWE
PRESS RELEASE

published on 03/22/2024 at 07:00, 1 year 9 months ago

ALSO Holding AG: thirteenth consecutive dividend increase
ALSO Holding AG announces thirteenth consecutive dividend increase of +586% since 2011, from CHF 0.70 to CHF 4.80. AGM approves dividend raise by CHF 0.20

Annual General Meeting Dividend Increase ALSO Holding AG Dividend Payout Thirteenth Consecutive
REGULATED PRESS RELEASE

published on 03/22/2024 at 07:00, 1 year 9 months ago

Biophytis a présenté son protocole de phase 3 dans le traitement de la sarcopénie
Biophy's présente son protocole de phase 3 pour traiter la sarcopénie lors de l'ICFSR. L'étude SARA-31 évaluera l'efficacité de RuvembriTM. Biophytis recherche des partenaires pour le développement

Biophytis RuvembriTM Sarcopénie Biophy's Protocole De Phase 3
REGULATED PRESS RELEASE

published on 03/22/2024 at 07:00, 1 year 9 months ago

Biophytis presented its phase 3 protocol in the treatment of sarcopenia
Biophytis presents phase 3 protocol for sarcopenia treatment at ICFSR conference, showcasing the potential of RuvembriTM. CEO Stanislas Veillet seeks partners for drug development and financing

Biophytis RuvembriTM Clinical-stage Biotechnology Phase 3 Protocol Sarcopenia Treatment

Accesswire

Published on 12/24/2025 at 21:10, 30 minutes ago

Golden Harp Resources Inc. Mails Management Information Circular for January 6, 2026 Annual and Special Meeting and Provides Additional Information Regarding Proposed Related Party Transaction
Published on 12/24/2025 at 15:25, 6 hours 15 minutes ago

CORRECTION: Nextech3D.ai Provides Shareholder Update on Krafty Labs Acquisition and Announces $321,917 CEO Investment
Published on 12/24/2025 at 14:59, 6 hours 41 minutes ago

Dynamite Blockchain Delivers Record Q3 2025
Published on 12/24/2025 at 14:00, 7 hours 40 minutes ago

Goldgroup Secures Ownership of the San Francisco Gold Mine Acquiring 100% of Molimentales del Noroeste, S.A. De C.V.
Published on 12/24/2025 at 14:00, 7 hours 40 minutes ago

Alta Copper Announces Filing and Mailing of Meeting Materials for the Special Meeting of Shareholders and Optionholders to be Held on January 26, 2026

View all ACCESSWIRE

EQS Group

Published on 12/24/2025 at 16:30, 5 hours 9 minutes ago

ABB Ltd: ABB share buybacks - December 18, 2025 - December 23, 2025
Published on 12/24/2025 at 15:07, 6 hours 33 minutes ago

Form 8.3 - The Vanguard Group, Inc.: American Axle & Manufacturing Holdings, Inc.
Published on 12/24/2025 at 15:06, 6 hours 33 minutes ago

Form 8.3 - The Vanguard Group, Inc.: JTC plc
Published on 12/24/2025 at 15:06, 6 hours 34 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 12/24/2025 at 15:05, 6 hours 35 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Greencore Group plc

Les Echos

Published on 12/23/2025 at 12:48, 1 day 8 hours ago

Evolution des droits de vote au 23 décembre 2025
Published on 12/23/2025 at 12:39, 1 day 9 hours ago

CDA - Acquisition of Sport4lux in Luxembourg
Published on 12/23/2025 at 12:35, 1 day 9 hours ago

CDA - Acquisition de Sport4lux au Luxembourg
Published on 12/22/2025 at 18:33, 2 days 3 hours ago

ABEO SE RENFORCE ET OBTIENT UNE TRÈS LARGE MAJORITÉ DU CAPITAL DE VOGO AVEC 90,84% DÉTENUS À L’ISSUE DE L’OFFRE RÉOUVERTE
Published on 12/22/2025 at 18:05, 2 days 3 hours ago

Covivio - Treasury shares transactions between December 15th , 2025 and December 19th, 2025

View all LES ECHOS COMFI WIRE